Actimed Therapeutics Further Expands Intellectual Property Portfolio for Lead Compound with New Composition of Matter Patent in Japan

Core Viewpoint - Actimed Therapeutics has strengthened its global intellectual property position with the granting of a new composition of matter patent for S-pindolol benzoate (ACM-001.1) by the Japan Patent Office, enhancing its coverage in key pharmaceutical markets [1][2][3]. Intellectual Property Protection - The newly granted Japanese patent provides broad protection for S-pindolol benzoate and its pharmaceutically acceptable forms, extending coverage beyond prior patents and complementing existing patents in the US and Europe [2]. - This patent ensures long-term exclusivity for a wide range of potential clinical applications, including cancer cachexia and other muscle-wasting conditions [2][3]. Clinical Development - Actimed is progressing S-pindolol benzoate through clinical development, including the ongoing PROACT Phase 2a program, which investigates its potential to reduce muscle-wasting in obese patients when used in combination with a GLP-1 receptor agonist [3][8]. - Previous studies have shown promising Phase 2a proof of concept data in cancer cachexia patients, and early non-clinical data suggests a potential role for S-pindolol benzoate in preserving muscle mass during weight loss [8]. Company Overview - Actimed Therapeutics is a clinical-stage specialty pharmaceutical company focused on advancing muscle health in cancer cachexia, obesity, and other muscle-wasting disorders [5]. - The company also owns global rights to S-oxprenolol (ACM-002), which is being developed for muscle wasting in amyotrophic lateral sclerosis (ALS) and has received US Orphan Drug Designation for this indication [9].